Castle Net Income From Continuing Ops from 2010 to 2026
| CSTL Stock | USD 32.37 0.14 0.43% |
Net Income From Continuing Ops | First Reported 2018-03-31 | Previous Quarter 4.5 M | Current Value -501 K | Quarterly Volatility 10.1 M |
Check Castle Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Castle Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 4 M, Net Interest Income of 14.9 M or Interest Income of 15.6 M, as well as many indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 1.53. Castle financial statements analysis is a perfect complement when working with Castle Biosciences Valuation or Volatility modules.
Castle | Net Income From Continuing Ops | Build AI portfolio with Castle Stock |
Historical Net Income From Continuing Ops data for Castle Biosciences serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Castle Biosciences represents a compelling investment opportunity.
Latest Castle Biosciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Castle Biosciences over the last few years. It is Castle Biosciences' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Castle Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Castle Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (13,668,071) | |
| Coefficient Of Variation | (185.72) | |
| Mean Deviation | 15,638,799 | |
| Median | (12,369,529) | |
| Standard Deviation | 25,384,113 | |
| Sample Variance | 644.4T | |
| Range | 93.7M | |
| R-Value | 0.03 | |
| Mean Square Error | 686.9T | |
| R-Squared | 0.0007 | |
| Significance | 0.92 | |
| Slope | 128,455 | |
| Total Sum of Squares | 10309.7T |
Castle Net Income From Continuing Ops History
About Castle Biosciences Financial Statements
Castle Biosciences investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Castle Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 16.4 M | 17.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Castle Biosciences Correlation against competitors. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. Projected growth potential of Castle fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Castle Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.52) | Earnings Share (0.44) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Castle Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Castle Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Castle Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.